Gilead to work with partners to ramp up production of potential coronavirus treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Dollar General stock jumps on earnings beat and raised guidance
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
JPMorgan Downgrades Gilead Sciences (GILD) to Neutral
May 1, 2020 5:36 AM EDTJPMorgan analyst Cory Kasimov downgraded Gilead Sciences (NASDAQ: GILD) from Overweight to Neutral with a price target of $85.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $81.17 yesterday.
... More